摘要
目的研究肺癌患者血清中CRP、CEA、NSE、CYFRA21-1联合检测在肺癌早期诊断中的应用价值。方法采用电化学发光免疫分析技术检测2010年1月—2013年12月因呼吸道疾病在就诊的336例肺癌患者、362例肺部良性疾病患者血清CEA、NSE、CYFRA21-1水平,并采用免疫透射比浊法检测两组患者的血清CRP水平,并比较两组各指标的阳性率以及单一或联合检测的灵敏度、特异度及阳性预测值。结果:肺癌组血清CRP、CEA、NSE、CYFRA21-1水平明显高于肺部良性疾病组,差异有统计学意义(P<0.05);肺癌组各指标阳性率明显高于良性组(P<0.05);联检指标可提高肺癌早期诊断的灵敏性。另外336例肺癌患者中吸烟者296人,约占88.09%。结论联合检测血清CRP、CEA、NSE、CYFRA21-1可提高肺癌早期的辅助诊断,为患者早期诊断及早期治疗提高重要依据。
Objective To study the value of combined detecting serum CRP、CEA、NSE、CYFRA21-1 in the diagnosis of the early lung cancer. Methods Electrochemical luminescence immunoassay technique to detect 336 cases of lung cancer patients、362 cas-es of lung benign disease patients serum CEA、NSE、CYFRA21-1 level,And compare the two groups and positive rate of each in-dex was single or joint detection sensitivity, specificity and positive predictive value. Results Lung cancer group of serum CRP、CEA、NSE、CYFRA21-1 level obviously higher than that of lung benign disease group, the difference was statistically significant (P〈0.05);Every index of Lung cancer group were significantly higher than in benign group, (P〈0.05);Joint inspection index can improve the sensitivity of lung cancer early diagnosis. Another 336 cases of patients with lung cancer in smokers, 296 people, about 88.09%. Conclusion Combined detection of serum CRP, CEA, NSE, CYFRA21-1 can improve the early auxiliary diagnosis of lung cancer, improve the important basis for patients with early diagnosis and early treatment.
出处
《中外医疗》
2015年第5期173-174,177,共3页
China & Foreign Medical Treatment